> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guideways launches AI platform to get life-changing medical devices to patients faster
- URL: https://med-techinsights.com/guideways-launches-ai-platform-to-get-life-changing-medical-devices-to-patients-faster/
- Published: 2026-04-09T12:30:56.000Z
- Updated: 2026-10-22T08:06:19.000Z
- Description: Guideways, an AI company which says it is built to solve the problem of regulatory complexity delaying the approval of thousands of medical technologies that could save or improve patient’s live, has launched its agentic AI platform to help medical device teams reach patients faster. The platform de
- Author: Oliver Johnson
- Tags: Digital Health & AI, News, Artificial Intelligence

[**Guideways**](https://guideways.ai/?ref=med-techinsights.com), an AI company which says it is built to solve the problem of regulatory complexity delaying the approval of thousands of medical technologies that could save or improve patient’s live, has launched its agentic AI platform to help medical device teams reach patients faster.

The platform deploys specialised AI agents that guide teams through FDA approval, from identifying the optimal regulatory strategy for a new device concept, to researching the applicable standards and requirements, to reviewing submissions for gaps.

Regulatory and compliance processes consume up to 75% of MedTech development costs and can push time to market back by 31 to 66 months. Two thirds of FDA submissions accepted for review receive a letter from the agency requiring additional work. Guideways’ platform is now available to medTech teams seeking FDA approval, cutting through some of the most time-consuming and costly steps in bringing a device to market.

Guideways applies agentic AI to automate the most demanding parts of regulatory work. Where generic AI tools produce unreliable outputs on complex regulatory questions, Guideways uses purpose-built agents and a curated knowledge base of more than 150,000 FDA reference documents, with expert workflows that mirror how experienced regulatory teams approach approval. The result is structured, explainable and traceable output that regulatory teams can review, document and defend.

Alexander Habermeier, Co-founder and CEO of Guideways: “With Guideways, we give medtech teams earlier regulatory clarity so they can move faster and make better decisions from day one. Behind every delayed or cancelled approval are patients waiting for better care. Our platform gives medtech teams the regulatory expertise they need, available at any time and cost effectively. While we launch with a focus on the U.S. FDA process, we are already expanding toward European MDR within our Explorers early access program.”

The Guideways platform launches with three specialised AI agents, each targeting a different phase of the FDA approval process:

- **FDA Sherpa** guides teams from a plain-language device concept to an underpinned regulatory approval strategy, showing how to get approved and what is required at each step.
- **FDA Reviewer** helps teams find gaps and inconsistencies in regulatory submissions before regulators do, reducing the risk of delays, questions and rework.
- **FDA Researcher** delivers deep, evidence-backed regulatory answers without the need to manually search and cross-reference dozens of documents.

[Bram van Rens](https://www.linkedin.com/in/bram-van-rens/?ref=med-techinsights.com), CTO and Co-Founder [PrecorDx](https://precordx.com/?ref=med-techinsights.com): “The regulatory landscape can be complicated for a startup developing a new-to-world modality like ours. Guideways allowed us to quickly map out possible paths to FDA clearance, giving us the confidence to move forward.”

[Liz Munro](https://www.linkedin.com/in/lizmunroconsulting/?ref=med-techinsights.com), Liz Munro Consulting said: “I routinely review regulatory precedent for early-stage companies. Guideways has automated this process, quickly analysing suitable product codes and predicates which I can review in detail when formulating the overall regulatory strategy. Guideways saves me time and I feel confident in the results (vs general AI which routinely hallucinates codes and devices).”

General-purpose large language models have shown consistent failure modes on regulatory tasks: invented product codes, contradictory pathway recommendations and logic that skips prerequisite checks. Guideways addresses these directly by grounding every output in validated regulatory data, applying specialist workflows that follow the actual decision logic of regulatory experts, and using multi-step reasoning to check prerequisites before proceeding.

Sander Denissen, Co-founder and CTO at Guideways: “Regulatory knowledge is scarce and often inaccessible. Progress stops when expertise is unavailable. We built Guideways to change that. You interact with the platform in natural language. It draws on over 150.0000 curated regulatory source documents to guide you from device description through classification, applicable controls, and in-depth technical file review. Every conclusion is traceable to exact sources: specific guidance pages, recognised standards, regulatory citations. This isn’t search. It’s an always-available regulatory support team.”

Guideways was founded early 2025 and closed its pre-seed financing in September 2025, backed by Healthy.Capital and Rising Star Venture Partners. In February 2026, the company launched early access to the platform through its Guideways Explorers program, onboarding an initial community of MedTech innovators ahead of today’s commercial launch. The platform is currently focused on the U.S. FDA approval process, with expansion toward European MDR and reimbursement frameworks planned in the coming months.